{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-26-000006","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.448804+00:00","generated_at":"2026-05-15T08:26:18.381515+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Connect Biopharma private placement $20.2M; Phase 1 IV rademikibart shows rapid bronchodilation; Phase 3 AD efficacy","bullets":["Raised $20.2M via private placement of 6.13M shares at $3.25; led by Panacea Venture; extends cash runway into H2 2027.","Phase 1 IV rademikibart: rapid FEV1 improvements of 200-400 mL within 15 mins in asthma/COPD, maintained through Day 29.","Phase 3 AD study: 96.6% EASI-75, 87.1% IGA 0/1, 85.3% EASI-90 at week 52; safety comparable to placebo, low conjunctivitis.","Phase 2 Seabreeze STAT data for acute exacerbations expected mid-2026; plans to meet FDA for Phase 3 alignment."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-26-000006","json":"https://secwatch.observer/filing/0001835268-26-000006.json","markdown":"https://secwatch.observer/filing/0001835268-26-000006.md","text":"https://secwatch.observer/filing/0001835268-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/0001835268-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/cntb-20260329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:26:18.381515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fe3319bacb63072c70c55ffabcf637e3ae37a35","claim":"Connect Biopharma Holdings Ltd entered into Purchase Agreement with the purchasers named therein valued at approximately $20.2 million (effective 2026-03-29).","evidence_excerpt":"On March 29, 2026, Connect Biopharma Holdings Limited (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 6,130,000 shares (the “Shares”) of the Company’s ordinary shares, par value $0.000174 per share (the “Ordinary Shares”), at a price of $3.25 per Share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/0001835268-26-000006-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein"},{"label":"Value","value":"approximately $20.2 million"},{"label":"Effective","value":"2026-03-29"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}